Tag Archives: SQNM

Illumina (NASDAQ:ILMN) Declares Sharp Boost in Fiscal Fourth Quarter Profit on Business Unit Sale

Posted on January 29, 2013 by Thomas Vedder

Illumina, Inc (NASDAQ:ILMN) announced a sharp boost in fiscal Q4 profit on Monday after the sale of a business unit to Amgen, Inc (NASDAQ:AMGN).

Genetic analysis Instrument Company booked a $48.6 million gain from the pre-tax sale of its stake …

Posted in Main Post, Technology | Tagged AFFX, Affymetrix, Illumina, ILMN, NASDAQ:AFFX, NASDAQ:ILMN, NASDAQ:SQNM, NYSE:PKI, PerkinElmer, PKI, Sequenom, SQNM | Comments Off

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) Updates Claim of a Healthy Pipeline

Posted on January 14, 2013 by Thomas Vedder

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) lately gave an update on its pipeline. Isis Pharmaclaims of a healthy pipeline. The firm thinks 5 of its pipeline candidates can get acceptance within the coming five years. Isis Pharmaanticipates data (phase II or phase …

Posted in Latest Headlines, Services | Tagged arena, ARNA, BMY, Bristol-Myers Squibb, Elan, ELN, ENZ, Enzo Biochem, GILD, Gilead Sciences, ISIS, ISIS Pharmaceuticals, JNJ, Johnson, MYL, Mylan, NASDAQ:ARNA, NASDAQ:GILD, NASDAQ:ISIS, NASDAQ:MYL, NASDAQ:SQNM, NYSE:BMY, NYSE:ELN, NYSE:ENZ, NYSE:JNJ, Sequenom, SQNM | Comments Off

Herbalife (NYSE:HLF) Symbolized as Compelling Buy below $70 – HLF, GMCR, LULU, DNDN, SQNM, MRK, PFE, HLF, CELG

Posted on January 11, 2013 by Thomas Vedder

On Friday DA Davison expert Timothy Ramey reported that Herbalife (NYSE:HLF)is a “compelling buy” at any price less than $70 per share, in spite of disapproval of the firm by hedge fund manager Bill Ackman of Pershing Square Capital Management. …

Posted in Healthcare, Latest Headlines | Tagged CELG, Celgene, Dendreon, DNDN, GMCR, Green Mountain Coffee, Herbalife, HLF, LULU, Lululemon Athletica, Merck, MRK, NASDAQ:CELG, NASDAQ:DNDN, NASDAQ:GMCR, NASDAQ:LULU, NASDAQ:SQNM, NYSE:HLF, NYSE:MRK, NYSE:PFE, PFE, Pfizer, Sequenom, SQNM | Comments Off

Illumina Inc. (NASDAQ:ILMN) Down to Knees after Roche Offer Refused – ILMN, LIFE, LMNX, VIVUS, VVUS, PFE, DNDN, HLF, SQNM

Posted on January 7, 2013 by Geoff Noir

Illumina Inc. (NASDAQ:ILMN)plunged almost 8.5% in premarket session on Monday following Roche Holding AG Chairman Franz Humer reported in an interview that the firm does not intend to purchase the gene sequencing expert.

Illumina(ILMN) is certainly off the table, Humerreported …

Posted in Healthcare, Latest Headlines | Tagged Dendreon, DNDN, Herbalife, HLF, Illumina, ILMN, LIFE, Life Technologies, LMNX, Luminex, NASDAQ:DNDN, NASDAQ:ILMN, NASDAQ:LIFE, NASDAQ:LMNX, NASDAQ:PPHM, NASDAQ:SQNM, NASDAQ:VVUS, NYSE:HLF, NYSE:PFE, Peregrine, PFE, Pfizer, Sequenom, SQNM, Vivus, VVUS | Comments Off

Emergent Biosolutions (NYSE:EBS) Issues FY 2012 Results; Revenue Misses Estimates – WPI, MYL, PPHM, VVUS, BSX, ILMN, SQNM, UNH

Posted on January 7, 2013 by Thomas Vedder

Emergent BiosolutionsInc (NYSE:EBS) on Monday reported its preliminary fiscal year 2012 financial results, projecting revenues slightly lower than Wall Street analysts’ forecasts. Biopharmaceutical Company also offered 2013 revenue outlook lower than forecasts.

The company projects net income in the range …

Posted in Healthcare, Latest Headlines | Tagged Boston Scientific, BSX, EBS, Emergent Biosolutions, Illumina, ILMN, MYL, Mylan, NASDAQ:ILMN, NASDAQ:MYL, NASDAQ:PPHM, NASDAQ:SQNM, NASDAQ:VVUS, NYSE:BSX, NYSE:EBS, NYSE:UNH, NYSE:WPI, Peregrine Pharmaceuticals, PPHM, Sequenom, SQNM, UNH, UnitedHealth, Vivus, VVUS, Watson Pharmaceuticals, WPI | Comments Off

Pfizer Inc., (NYSE:PFE) Lowering Sales Force, Working on New Drugs – PFE, MRK, NVS, SQNM, HEB, ARNA, ONTY, MYL, ESRX

Posted on December 19, 2012 by Thomas Vedder

Pfizer Inc., (NYSE:PFE) the New York health-care specialized firm, would lower almost a fifth of its 3,000-member sales force for primary-care pharmaceuticals as an element of an ongoing cost-lowering attempt, a person closely related with the issue informed Bloomberg News. …

Posted in Healthcare, Latest Headlines | Tagged arena, ARNA, ESRX, Express Scripts, HEB, Hemispherx BioPharma, Merck, MRK, MYL, Mylan, NASDAQ:ARNA, NASDAQ:ESRX, NASDAQ:MYL, NASDAQ:ONTY, NASDAQ:SQNM, Novartis, NVS, NYSE:MRK, NYSE:NVS, NYSE:PFE, NYSEAMEX:HEB, Oncothyreon, ONTY, PFE, Pfizer, Sequenom, SQNM | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.